Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study

References

• Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 2001;104:2118-50
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, de Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderón A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Estudio Val-FAAP. Rev Esp Cardiol 2012;65:47-53
   PubMed Web of Science ®Google Scholar
• Potpara TS, Jokic V, Medic B. An update on atrial fibrillation: focus on stroke risk reduction strategies. Minerva Med 2015;106:259-73
   PubMed Web of Science ®Google Scholar
• Hernández Olmedo M, Suárez Fernández C. Progress of anticoagulation therapy in atrial fibrillation. Med Clin (Barc) 2015;145:124-30
   PubMed Web of Science ®Google Scholar
• de Andrés-Nogales F, Oyagüez I, Betegón-Nicolás L, et al. Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF Study. Rev Clin Esp 2015;215:73-82
   PubMed Web of Science ®Google Scholar
• Navarro JL, Cesar JM, Fernández MA, et al. Morbidity and mortality in patients treated with oral anticoagulants. Rev Esp Cardiol 2007;60:1226-32
   PubMed Web of Science ®Google Scholar
• Cotté FE, Benhaddi H, Duprat-Lomon I, et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in 4 European countries. Clin Ther 2014;36:1160-8
   PubMed Web of Science ®Google Scholar
• Polo García J. New anticoagulants against classic anticoagulants: advantages and disadvantages. Semergen 2013;39:10-16
   Google Scholar
• Mateo J. News anticoagulants and rol y clinical practice. Rev Esp Cardiol 2013;13(Suppl C):33-41
   Google Scholar
• Jurcuţ R, Militaru S, Geavlete O, et al. Predictive factors for obtaining a correct therapeutic range using antivitamin K anticoagulants: a tertiary center experience of patient adherence to anticoagulant therapy. Patient Prefer Adherence 2015;9:1271-8
   PubMed Web of Science ®Google Scholar
• Skeppholm M, Friberg L. Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol 2014;103:998-1005
   PubMed Web of Science ®Google Scholar
• Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2016;115:31-9
   PubMed Web of Science ®Google Scholar
• Miller CS, Grandi SM, Shimony A, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453-60
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Camm AJ, Amarenco P, Haas S, et al. xantus: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145-53
   PubMed Web of Science ®Google Scholar
• Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94
   PubMed Web of Science ®Google Scholar
• Márquez-Contreras E, Gil-Guillén VF, De La Figuera-Von Wichmann M, et al. Do patients with high vascular risk take antihypertensive medication correctly? Rev Esp Cardiol 2012;65:544-50
   PubMed Web of Science ®Google Scholar
• De Schryver EL, van Gijn J, Kappelle LJ, et al.; Dutch TIA trial and SPIRIT study groups. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. Neurol 2005;252:1316-21
   Web of Science ®Google Scholar
• Márquez-Contreras E. Practice evaluation of noncompliance. Hipertensión 2008;25:205-13
   Google Scholar
• Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens 2009;27:1540-51
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Thomson E, et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrilation. Curr Med Res Opin 2015;31:1831-40
   PubMed Web of Science ®Google Scholar
• Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin 2015;31:1889-95
   PubMed Web of Science ®Google Scholar
• Rubboli A. Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter? Curr Med Res Opin 2015;31:1845-47
   PubMed Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Skjøth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495-504
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9
   PubMed Web of Science ®Google Scholar
• Clua-Espuny JL, Lechuga-Duran I, Bosch-Princep R, et al. Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. Rev Esp Cardiol 2013;66:545-52
   PubMed Web of Science ®Google Scholar
• Giménez-García E, Clua-Espuny JL, Bosch-Princep R, et al. The management of atrial fibrillation and characteristics of its current care in outpatients. AFABE observational study. Aten Primaria 2014;46:58-67
   PubMed Web of Science ®Google Scholar
• Amin A, Marrs JC. Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost 2016;22:605-16
   PubMed Web of Science ®Google Scholar
• Haynes RB, Ackloo E, Sahota N, et al. Intervenciones para mejorar la adherencia a la medicación (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 4. Oxford: Update Software Ltd. Available at: http://www.update-software.com. Last accessed June 20, 2016
   Google Scholar
• Van Onzenoort HA, Verberk WJ, Kessels AG, et al. Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension. Am J Hypertens 2010;23:149-54
   PubMed Web of Science ®Google Scholar
• Burnier M, Schneider MP, Chioléro A, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001;19:335
   PubMed Web of Science ®Google Scholar
• Baulmann J, Düsing R, Vetter H, Mengden T. Therapy resistant hypertension – significance of electronic compliance monitoring. Dtsch Med Wochenschr 2002;127:2379-82
   PubMed Web of Science ®Google Scholar